CG Oncology financials
$69.89+0.40%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $1.1M | $2.3M | $1.7M | $0.00 | $52.0K | $456.0K | $43.0K | $111.0K | $529.0K |
| Gross profit | -$2.8M | -$1.9M | -$748.0K | $89.0K | $0.00 | $52.0K | $456.0K | $43.0K | $111.0K | $529.0K |
| Gross margin | −239.2% | −173.5% | −32.2% | 5.3% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$86.4M | -$66.4M | -$48.7M | -$51.1M | -$48.7M | -$42.2M | -$38.0M | -$28.3M | -$25.9M | -$22.5M |
| Net income | -$79.1M | -$60.2M | -$41.3M | -$43.8M | -$41.4M | -$34.5M | -$31.8M | -$20.4M | -$18.9M | -$16.9M |
| Net margin | −6832.8% | −5558.8% | −1779.0% | −2629.5% | — | −66253.8% | −6973.2% | −47453.5% | −17028.8% | −3201.1% |
| Diluted EPS | $-0.90 | $-0.71 | $-0.52 | $-0.57 | $-0.54 | $-0.45 | $-0.46 | $-0.30 | $-0.28 | $-0.36 |
| EBITDA | -$85.6M | -$65.5M | -$47.9M | -$50.7M | -$48.6M | -$42.2M | -$38.0M | -$28.3M | -$25.8M | -$22.5M |
| Operating cash flow | -$46.4M | -$56.9M | -$36.2M | -$38.9M | -$28.0M | -$29.3M | -$20.7M | -$15.9M | -$16.1M | -$26.0M |
| Free cash flow | -$46.9M | -$57.2M | -$36.2M | -$39.0M | -$28.0M | -$29.3M | -$20.9M | -$15.9M | -$16.1M | -$26.0M |
| Diluted shares | 88.2M | 84.5M | 80.1M | 76.7M | 76.2M | 76.2M | 69.1M | 67.1M | 66.6M | 47.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.6M | $33.7M | $32.5M | $45.1M | $14.6M | $41.5M |
| Short-term investments | $1.01B | $1.04B | $709.7M | $635.1M | $646.4M | $647.0M |
| Total debt | $3.0M | $3.0M | $3.0M | $3.0M | $0.00 | $0.00 |
| Total assets | $1.09B | $1.14B | $791.6M | $729.9M | $701.4M | $728.2M |
| Total liabilities | $56.5M | $43.5M | $39.0M | $42.3M | $31.1M | $23.4M |
| Shareholders' equity | $1.03B | $1.09B | $752.6M | $687.6M | $670.4M | $704.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology